Proto Labs (PRLB) COO updates Form 4 for option exercise and 3,048-share sale

Q: What insider transaction did Proto Labs (PRLB) report in this Form 4/A?

The Chief Operations Officer exercised 3,048 employee stock options at $33.84 per share and sold 3,048 common shares on November 25, 2025 under a pre-arranged plan.

Q: What prices were involved in the Proto Labs (PRLB) COO’s stock transactions?

The officer exercised options with an exercise price of $33.84 per share and sold the resulting shares at a weighted average price of $50.1741 per share, with individual sale prices ranging from $50.00 to $50.53 .

Q: Was the Proto Labs (PRLB) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the 3,048 shares sold on November 25, 2025 were sold under a Rule 10b5-1 plan adopted on August 15, 2025 .

Q: What correction does this amended Form 4/A make for Proto Labs (PRLB)?

The amendment corrects the expiration date of the employee stock options to February 14, 2026 , noting it fixes a clerical error in the original report while all transaction details were correctly reported before.

Q: Does the Form 4/A mention Proto Labs (PRLB) Employee Stock Purchase Plan shares?

Yes. It notes that the officer’s holdings include 57 shares of common stock purchased on November 15, 2025 through the company’s Employee Stock Purchase Plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Proto Labs Inc. Chief Operations Officer reported an amended insider transaction involving company common stock. On November 25, 2025, the officer exercised 3,048 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares. That same day, the officer sold 3,048 common shares at a weighted average price of $50.1741 per share under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025. After these transactions, the officer beneficially owned 28,898 common shares directly. The filing also clarifies that the stock options were fully vested and corrects the stated expiration date of the options to February 14, 2026, fixing a clerical error in a prior report while leaving all other transaction details unchanged.

Insider Trade Summary

Net Seller: 3,048 shares ($152,931)

Net Sell 3 txns

Insider Kenison Michael R.

Role Chief Operations Officer

Sold 3,048 shs ($153K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	3,048	$0.00	--
Exercise	Common Stock	3,048	$33.84	$103K
Sale	Common Stock	3,048	$50.1741	$153K

Holdings After Transaction: Employee Stock Option (right to buy) — 0 shares (Direct); Common Stock — 31,946 shares (Direct)

Footnotes (1)

Includes 57 shares of Common Stock of the issuer purchased on November 15, 2025 through the issuer's Employee Stock Purchase Plan program. These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Reflects the weighted average price of 3,048 shares of Common Stock of the issuer sold by the Reporting Person in multiple transactions on November 25, 2025 with sale prices ranging from $50.00 to $50.53 per share. The Reporting Person undertakes to provide upon request by U.S. Securities and Exchange Commission staff, the issuer, or a securityholder of the issuer full information regarding the number of shares sold at each separate price. Fully vested. This amendment reflects an adjustment to the expiration date of the Employee Stock Options to correct a clerical error in the reporting person's Form 4 filed on November 25, 2025. All transaction details were accurately reported on the original Form 4.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

12/03/2025 - 06:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kenison Michael R.

(Last)

(First)

(Middle)

5540 PIONEER CREEK DRIVE

(Street)

MAPLE PLAIN

55359

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Proto Labs Inc [ PRLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/26/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/25/2025		M		3,048	A	$33.84	31,946⁽¹⁾	D
Common Stock	11/25/2025		S		3,048⁽²⁾	D	$50.1741⁽³⁾	28,898	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$33.84	11/25/2025		M			3,048	⁽⁴⁾	02/14/2026⁽⁵⁾	Common Stock	3,048	$0	0	D

Explanation of Responses:

1. Includes 57 shares of Common Stock of the issuer purchased on November 15, 2025 through the issuer's Employee Stock Purchase Plan program.

2. These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025.

3. Reflects the weighted average price of 3,048 shares of Common Stock of the issuer sold by the Reporting Person in multiple transactions on November 25, 2025 with sale prices ranging from $50.00 to $50.53 per share. The Reporting Person undertakes to provide upon request by U.S. Securities and Exchange Commission staff, the issuer, or a securityholder of the issuer full information regarding the number of shares sold at each separate price.

4. Fully vested.

5. This amendment reflects an adjustment to the expiration date of the Employee Stock Options to correct a clerical error in the reporting person's Form 4 filed on November 25, 2025. All transaction details were accurately reported on the original Form 4.

Remarks:

	/s/ Kareem S. Tawfic, Attorney-in-Fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Proto Labs (PRLB) report in this Form 4/A?

The Chief Operations Officer exercised 3,048 employee stock options at $33.84 per share and sold 3,048 common shares on November 25, 2025 under a pre-arranged plan.

What prices were involved in the Proto Labs (PRLB) COO’s stock transactions?

The officer exercised options with an exercise price of $33.84 per share and sold the resulting shares at a weighted average price of $50.1741 per share, with individual sale prices ranging from $50.00 to $50.53.

How many Proto Labs (PRLB) shares does the reporting officer own after the transactions?

After the reported transactions, the Chief Operations Officer directly beneficially owned 28,898 shares of Proto Labs common stock.

Was the Proto Labs (PRLB) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the 3,048 shares sold on November 25, 2025 were sold under a Rule 10b5-1 plan adopted on August 15, 2025.

What correction does this amended Form 4/A make for Proto Labs (PRLB)?

The amendment corrects the expiration date of the employee stock options to February 14, 2026, noting it fixes a clerical error in the original report while all transaction details were correctly reported before.

Are the Proto Labs (PRLB) employee stock options reported here fully vested?

Yes. The explanation section specifies that the reported employee stock options are fully vested.

Does the Form 4/A mention Proto Labs (PRLB) Employee Stock Purchase Plan shares?

Yes. It notes that the officer’s holdings include 57 shares of common stock purchased on November 15, 2025 through the company’s Employee Stock Purchase Plan.